Study guide
8.5 Evidence-Based Practice, Discharge Education & Quality Improvement
Transplantation and Cellular Therapy Certified Nurse TCTCN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy
2 Chapter 2: Foundations of Transplantation & Cellular Biology
2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum
3 Chapter 3: Product Collection, Processing & Infusion Procedures
3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking
4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease
4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes
5 Chapter 5: Post-Transplant Infections & Supportive Care
5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition
6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS
6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy
7 Chapter 7: Chronic GVHD & Long-Term Survivorship
7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment
8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards
8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement
8.5 Evidence-Based Practice, Discharge Education & Quality Improvement
Key Takeaways Explain This Topic AI
Evidence-based practice combines current evidence, clinical expertise, patient values and local data; QI improves a local process, while research seeks generalizable knowledge under applicable human-subject protections.
Febrile neutropenia requires rapid assessment, indicated cultures and prompt protocol-selected antipseudomonal antibiotics—commonly within 60 minutes—without waiting for imaging; sepsis stabilization occurs in parallel.
Discharge education is iterative and uses plain language, qualified interpreters, demonstration and teach-back for the actual product/program plan, medicines, fever response, food/environment safety and urgent symptoms.
Scope comes from law, licensure, competence, employer policy, orders/delegation and product procedures; TCTCN certification validates specialty knowledge but does not independently expand legal scope.
Programs should address moral distress, burnout and secondary traumatic stress through psychologically safe escalation, workload/system improvement, peer support, debriefing and confidential assistance—not only individual resilience.
Last updated: September 2026
Evidence-Based Practice, Education, Quality Improvement and Professional Safety
Clinical principle: Reliable TCT nursing joins current evidence with clinical expertise, patient values and local outcomes. Product labels and controlled protocols set the action; nurses monitor, communicate, escalate and improve the system within scope.
1. EBP, QI and Research
Evidence-based practice asks how the best current evidence should inform care. Appraise source quality, population, effect size, harms, feasibility and patient preferences before adapting a bundle. Quality improvement measures a local process against a standard, tests change and monitors balancing measures. Research is designed to create generalizable knowledge and requires scientific review, consent and human-subject/privacy protections. A clinical consent does not replace research consent. Nurses report deviations and adverse events without independently changing or unblinding an intervention.
A CAPA/QI project should define the problem and denominator, examine causes, select a change, measure process/outcome/balancing indicators, and decide whether improvement is sustained. Examples include central-line infection, time to antibiotic, identity discrepancies, product temperature excursion, falls or medication errors. A zero-event month alone does not prove effectiveness.
2. Infection and Supportive-Care Reliability
For febrile neutropenia, IDSA criteria use one oral temperature at least 38.3°C or at least 38.0°C sustained for an hour with ANC below 500/mcL or expected decline. HCT programs often direct patients to call for a single 38.0°C reading. Assess sepsis immediately; obtain central-lumen and peripheral cultures as indicated if they do not delay treatment; administer the protocol-selected IV antipseudomonal agent promptly, commonly within 60 minutes. Adjust for allergy, organ function and local resistance. Imaging, urine and other tests are symptom-directed.
Central-line bundles include hand hygiene, aseptic access, appropriate antisepsis, hub disinfection, dressing integrity and daily necessity review. CHG product/concentration, scrub/dry time and dressing interval follow age, line and policy; no one number is universal. Oral care uses gentle brushing and bland rinses with regimen-specific oral cryotherapy for high-dose melphalan when feasible. During severe cytopenia/mucositis, avoid traumatic rectal procedures and adjust dental, injection and fall/bleeding precautions to count, symptoms and policy.
3. Discharge Education and Teach-Back
Begin education early, divide it into manageable sessions and use the patient's preferred language and communication format. Qualified interpreters support clinical teaching; chosen family may participate with permission but should not replace an interpreter. Plain language and accessible, user-tested materials are more important than one claimed grade level.
Use teach-back as a check of the explanation: “To be sure I explained it clearly, show me how you will use the thermometer and whom you will call.” Re-explain without blaming the learner and verify any hands-on task assigned at home. Document the plan, barriers and backup.
Teach the program's fever threshold and to call before self-treating unless the team has given another instruction. Review the prescribed medication schedule and which doses, if any, are held before a trough—never hold every clinic-day dose by default. Include vomiting/missed-dose instructions and interaction review. Teach food safety: avoid unpasteurized products, raw/undercooked animal foods, raw sprouts and unsafe buffet/cross-contamination exposures during the defined risk period. Environmental teaching emphasizes hand hygiene, safe pets/animal waste, avoidance of gardening/soil and construction/mold dust during high risk, and sun protection; it does not require removing every household flower for every survivor.
Product-specific urgent symptoms include fever/rigors, dyspnea, hypotension/syncope, confusion/language or handwriting change, seizure, rash, jaundice/weight gain, bleeding, low urine output, severe diarrhea/vomiting and inability to take medicines. Provide a 24/7 number and specify when to call emergency services.
4. Scope, Communication and Environmental Safety
Accept only activities allowed by the nurse practice act/regulation, employer privilege/policy, verified competence, order/protocol and delegation rules. Certification does not authorize prescribing, independent product release/manipulation or practice beyond licensure. Use structured handoffs and closed-loop emergency communication; document assessment, notification, orders, response and deviations. Speak up and stop the process for identity, product, dose, storage, consent or safety discrepancies.
Environmental safety includes hazardous-drug personal protective equipment (PPE) and disposal, radiation precautions, sharps/biohazards, infection isolation, cryogenic and DMSO exposure controls, ergonomics and exposure reporting. Follow SDS, engineering controls and occupational-health pathways rather than improvising after a spill.
5. Professional Development and Team Well-being
Maintain continuing education, product/role competencies, mock emergencies and awareness of revised labels, guidelines and SOPs. Moral distress occurs when a clinician perceives the ethically appropriate action but faces constraints. Burnout reflects chronic workplace stress; secondary traumatic stress can involve intrusive memories, avoidance and hyperarousal after repeated trauma exposure. Escalate immediate impairment or safety risk compassionately.
Effective support combines system measures—adequate staffing/workload, ethical consultation, psychological safety, recovery time and leadership response—with peer debriefing, mentorship, Schwartz Rounds or similar forums, and confidential counseling. Self-care can help but does not replace correction of unsafe organizational conditions.
Loading diagram... Discharge Education, Escalation and Nursing Resilience
6. Telling Evidence-Based Practice, Quality Improvement and Research Apart
Items that ask a nurse to classify a proposed project turn on three questions, and confusing the categories is a reliable source of lost points.
Purpose. Evidence-based practice applies existing evidence to local care. Quality improvement improves a specific local process against a local target. Research generates new knowledge intended to be generalizable beyond the setting.
Oversight. Research involving human subjects requires review by an institutional review board and, ordinarily, informed consent from participants. EBP and QI projects generally proceed under institutional quality or practice governance without IRB review - but the boundary is determined by intent to generalize, so a QI project that is designed for publication and generalization may require review. When uncertain, the correct action is to ask the IRB rather than to decide independently.
Method. QI uses iterative small-scale cycles such as plan-do-study-act with rapid measurement and adjustment. Research follows a fixed protocol with a defined design, sample, and analysis plan that cannot be altered mid-study without formal amendment.
A worked example: adopting a validated oral care bundle because the literature supports it is EBP; running successive small tests to raise documented completion of that bundle from 60 to 95 percent on one unit is QI; enrolling patients in a randomized comparison of two bundles to determine which reduces mucositis is research.